Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Georgia's Lion Finance reports 39pc rise in first-quarter profit

(Sharecast News) - Lion Finance Group reported a 39% year-on-year rise in first-quarter profit to GEL 513.1m (£141.14m), driven by strong performances in Georgia and Armenia and continued leadership in digital banking. The FTSE 250 company, formerly known as Bank of Georgia Group, achieved a return on average equity of 28.7%, with its Georgian and Armenian units contributing GEL 405.1m and GEL 95.5m in profit respectively.

Digital channels accounted for 85% of loans and 74% of deposits, while customer satisfaction with its mobile apps remained high.

The results reflected robust macroeconomic conditions, with Georgia's economy expanding 9.3% and Armenia's by 4.1% in the quarter, supporting loan growth and operational momentum.

Ameriabank, fully consolidated in March last year, now represented a quarter of group assets and underpinned Lion's 20.3% market share in Armenian loans.

Group-wide, market share stood at 37.3% in Georgia.

Lion Finance said it was maintaining a strong capital position, with CET1 ratios of 16.4% for Bank of Georgia and 14.7% for Ameriabank, enabling continued investment in growth and shareholder returns.

The company reaffirmed its strategic targets, including annual loan book growth of around 15% and ROAE exceeding 20%, while distributing 30% to 50% of earnings through dividends and buybacks.

At 0924 BST, shares in Lion Finance Group were down 9.81% at 6,087.61p.

Reporting by Josh White for Sharecast.com.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.